SMARCA4 loss leads to CD44 overexpression and BRCA1 impairment, further driving proliferation and inhibiting DNA repair.5,12 Finally, BRG1 antagonizes MYC, and its loss allows cancer cells to activate growth factor receptors independently, preventing differentiation (Figure 3).13 This evidence concerns the gene SMARCA4 and cancer.